Bright Minds Biosciences to Present at Piper Sandler 37th Annual Healthcare Conference and 2025 AES Annual Meeting

Rhea-AI Summary

Bright Minds Biosciences (NASDAQ: DRUG) will present at two industry events in early December 2025 highlighting its work on selective 5-HT2 agonists for drug-resistant epilepsy, depression, and other CNS disorders.

Events and schedule: Piper Sandler 37th Annual Healthcare Conference on Dec 3, 2025 at 11:30am ET, and the 2025 American Epilepsy Society Annual Meeting scientific exhibit session on Dec 7, 2025 from 2:00pm–5:00pm ET. The appearances provide investor and scientific audiences opportunities to hear updates and view the company’s scientific exhibit.

News Market Reaction

+0.96%

5 alerts

+0.96% News Effect

+$4M Valuation Impact

$467M Market Cap

0.5x Rel. Volume

On the day this news was published, DRUG gained 0.96%, reflecting a mild positive market reaction. Our momentum scanner triggered 5 alerts that day, indicating moderate trading interest and price volatility. This price movement added approximately $4M to the company's valuation, bringing the market cap to $467M at that time.

Data tracked by StockTitan Argus on the day of publication.

NEW YORK, Nov. 25, 2025 (GLOBE NEWSWIRE) -- Bright Minds Biosciences, Inc. (“Bright Minds,” “BMB” or the “Company”) (NASDAQ: DRUG), a pioneering company focused on developing highly selective 5-HT2 agonists for the treatment of drug-resistant epilepsy, depression, and other central nervous system (CNS) disorders, today announced that the Company will participate in the following upcoming events:

	EVENT:	Piper Sandler 37th Annual Healthcare Conference
	DATE:	Wednesday, December 3, 2025
	TIME:	11:30am ET
	EVENT:	2025 American Epilepsy Society Annual Meeting – Scientific Exhibit Session
	DATE:	Sunday, December 7, 2025
	TIME:	2pm – 5pm ET

About Bright Minds Biosciences

Bright Minds Biosciences is a biotechnology company developing innovative treatments for patients with neurological and psychiatric disorders. Our pipeline includes novel compounds targeting key receptors in the brain to address conditions with high unmet medical need, including epilepsy, depression, and other CNS disorders. Bright Minds is focused on delivering breakthrough therapies that can transform patients’ lives.

Bright Minds Biosciences has developed a unique platform of highly selective serotonergic agonists exhibiting selectivity at different serotonergic receptors. This has provided a rich portfolio of NCE programs within neurology and psychiatry.

Contact Information

Investor Relations
Lisa M. Wilson
T: 212-452-2793
E: lwilson@insitecony.com

FAQ

When will Bright Minds Biosciences (DRUG) present at the Piper Sandler Healthcare Conference?

Bright Minds will present on Dec 3, 2025 at 11:30am ET.

What is the date and time for Bright Minds' exhibit at the 2025 American Epilepsy Society meeting?

The scientific exhibit session is scheduled for Dec 7, 2025 from 2:00pm–5:00pm ET.

What topics will Bright Minds Biosciences (DRUG) cover at the December 2025 events?

The company will highlight its development of selective 5-HT2 agonists for drug-resistant epilepsy, depression, and other CNS disorders.

How can investors find Bright Minds' presentation details for the Dec 3, 2025 Piper Sandler event?

Investors should check the Piper Sandler conference schedule and Bright Minds investor relations for presentation access and timing details.

Will Bright Minds (DRUG) provide scientific materials at the American Epilepsy Society exhibit on Dec 7, 2025?

The company will participate in a scientific exhibit session, where attendees can view the company’s exhibit and related materials during the 2:00pm–5:00pm ET slot.

Do these December 2025 events signal a regulatory or financial update from Bright Minds (DRUG)?

The announcements list presentation and exhibit dates and times; they do not include specific regulatory decisions or financial guidance.